about
Identification of novel Mycobacterium tuberculosis CD4 T-cell antigens via high throughput proteome screening.Learning from the past for TB drug discovery in the futureLooking back to the future: predicting in vivo efficacy of small molecules versus Mycobacterium tuberculosisA subset of circulating blood mycobacteria-specific CD4 T cells can predict the time to Mycobacterium tuberculosis sputum culture conversionA Web-Based Platform for Designing Vaccines against Existing and Emerging Strains of Mycobacterium tuberculosisClofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study.Targeting Mycobacterium tuberculosis topoisomerase I by small-molecule inhibitors.Syntheses and evaluation of substituted aromatic hydroxamates and hydroxamic acids that target Mycobacterium tuberculosis.The Biosynthesis of Capuramycin-type Antibiotics: IDENTIFICATION OF THE A-102395 BIOSYNTHETIC GENE CLUSTER, MECHANISM OF SELF-RESISTANCE, AND FORMATION OF URIDINE-5'-CARBOXAMIDE.Tissue distribution of pretomanid in rat brain via mass spectrometry imaging.Significant Effects of Oral Phenylbutyrate and Vitamin D3 Adjunctive Therapy in Pulmonary Tuberculosis: A Randomized Controlled Trial.Myeloid Growth Factors Promote Resistance to Mycobacterial Infection by Curtailing Granuloma Necrosis through Macrophage ReplenishmentNovel targeting of PEGylated liposomes for codelivery of TGF-β1 siRNA and four antitubercular drugs to human macrophages for the treatment of mycobacterial infection: a quantitative proteomic study.QSAR based therapeutic management of M. tuberculosis.Syntheses and Biological Evaluations of Highly Functionalized Hydroxamate Containing and N-Methylthio Monobactams as Anti-Tuberculosis and β-Lactamase Inhibitory Agents.Short, Synthetic Cationic Peptides Have Antibacterial Activity against Mycobacterium smegmatis by Forming Pores in Membrane and Synergizing with Antibiotics.Advances in Drug Discovery and Development for Pediatric Tuberculosis.Paradoxical Hypersusceptibility of Drug-resistant Mycobacteriumtuberculosis to β-lactam Antibiotics.A systems framework for vaccine design.Novel diagnostics and therapeutics for drug-resistant tuberculosis.Synthesis and biological evaluation of 1,2,4-triazole-3-thione and 1,3,4-oxadiazole-2-thione as antimycobacterial agents.Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline.News on therapeutic management of MDR-tuberculosis: a literature review.Antimycobacterial activity of DNA intercalator inhibitors of Mycobacterium tuberculosis primase DnaG.Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes.N-substituted 2-isonicotinoylhydrazinecarboxamides--new antimycobacterial active molecules.Identification of promising DNA GyrB inhibitors for Tuberculosis using pharmacophore-based virtual screening, molecular docking and molecular dynamics studies.Synthesis and evaluation of copper(II) complexes with isoniazid-derived hydrazones as anticancer and antitubercular agents.
P2860
Q27303136-40F1CBEC-0AD8-40BB-B924-F9ACBAAEB431Q27485405-A73D6CDB-0B8A-44D8-9AF5-DBB09B2F2461Q28538272-001CCD85-BC8C-4DAE-A017-249730BED4C6Q28541001-2711B44A-FAA8-467F-B415-195675AA78BAQ28551471-A766AF59-0D11-44A9-A1A7-ECBFA25E6458Q34331039-676C509B-673C-4F1B-AC9B-05455320C471Q35532866-0E9DA36D-AF36-4722-B0DC-7EA10869FEDEQ35650399-278DA6A5-9B96-4653-B457-28BDFF5840FBQ35662238-F974A63C-8A3F-4D23-A422-A9FF08D3B6AEQ35710470-21D78975-3BDE-46B6-B97A-F7D1D9CE96B9Q35783492-B479CC48-19DB-4817-9C8C-09D8F08E8E58Q35871700-A23A9732-FC27-4ADD-A2C4-9CE1092B364FQ35950533-CAAA0E5F-E6BA-4CDA-963A-4C78EB6EA925Q36359056-5CE38BA6-DA40-4125-8349-0EF01F3A5B29Q36603702-005434E1-514F-46FF-A386-CF89CEF17F81Q36683469-1DF781BF-6258-4FE8-B390-0F5BE132538EQ37134041-52A080D4-8296-4FDD-909F-87DB3662DD5CQ37149906-1ED19F0F-C3AE-45E2-B389-DEF94419A4C0Q37698015-D12DE8A8-98FB-4637-96C5-A9D6E778CCD9Q38210363-7F686D5A-1402-490D-BC65-0541BC7C3A9DQ38721512-06603E7E-4B87-41CC-B4ED-3535BD0DFA6EQ38995175-03D757E3-6508-4D72-9178-EC6483296547Q39398924-131C08C7-87AE-42EC-B328-342452AE1F4FQ42186282-BE2C1ED1-9767-4AEE-BC57-A4B8759FD496Q42281128-21C73A45-0B92-4968-B449-DE7106528F3BQ42706161-D16F5C66-B565-4A17-BD89-E62C39029977Q48327385-EDA07397-599D-41E1-80BE-D77966DB75F4Q48371677-44AE0063-E52F-4145-8EAB-69BBD1845D6A
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Rising to the challenge: new therapies for tuberculosis
@ast
Rising to the challenge: new therapies for tuberculosis
@en
Rising to the challenge: new therapies for tuberculosis
@nl
type
label
Rising to the challenge: new therapies for tuberculosis
@ast
Rising to the challenge: new therapies for tuberculosis
@en
Rising to the challenge: new therapies for tuberculosis
@nl
prefLabel
Rising to the challenge: new therapies for tuberculosis
@ast
Rising to the challenge: new therapies for tuberculosis
@en
Rising to the challenge: new therapies for tuberculosis
@nl
P2860
P3181
P1476
Rising to the challenge: new therapies for tuberculosis
@en
P2093
Emily B Wong
William R Bishai
P2860
P304
P3181
P356
10.1016/J.TIM.2013.05.002
P407
P577
2013-06-11T00:00:00Z